Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  NeuBase Therapeutics, Inc.    NBSE

NEUBASE THERAPEUTICS, INC.

(NBSE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

NeuBase Therapeutics to Present at Upcoming Investor Conferences in September 2020

share with twitter share with LinkedIn share with facebook
09/08/2020 | 09:01am EDT

22nd Annual H.C. Wainwright Global Investor Conference presentation at 1:30 p.m. ET on September 16TH

Oppenheimer Fall Healthcare LifeSciences & Medtech Summit Fireside Chat at 10:00 a.m. ET on September 23RD

PITTSBURGH, Sept. 08, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview at the virtual H.C. Wainwright 22nd Annual Global Investment Conference, as well as participate in a fireside chat at the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, which are both being held in September 2020.

Conference Details:
Event:H.C. Wainwright 22nd Annual Global Investment Conference (virtual)
Format:Presentation
Date:Wednesday, September 16TH
Time:1:30 p.m. ET
Location:Webcast Link - or at the company’s website (click here)
  
  
Event:Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (virtual)
Format:Fireside Chat
Date:Wednesday, September 23RD
Time:10:00 a.m. ET
Location:Webcast Link - or at the company’s website (click here)

About NeuBase Therapeutics
NeuBase is accelerating the genetic revolution using a new class of synthetic medicines. NeuBase’s designer PATrOL™ therapies are centered around its proprietary drug scaffold to address genetic diseases at the source by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions. To learn more, visit www.neubasetherapeutics.com.

NeuBase Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors, LLC
Daniel@lifesciadvisors.com
OP: (617) 430-7576

NeuBase Media Contact:
Cait Williamson, Ph.D.
LifeSci Public Relations
cait@lifescipublicrelations.com
OP: (646) 751-4366

 

Primary Logo

© GlobeNewswire 2020

share with twitter share with LinkedIn share with facebook
All news about NEUBASE THERAPEUTICS, INC.
10/14NEUBASE THERAPEUTICS : Announces Addition of Peter Nielsen, Ph.D., Inventor of P..
AQ
10/13NEUBASE THERAPEUTICS : Announces Addition of Peter Nielsen, Ph.D., Inventor of P..
AQ
10/13NeuBase Therapeutics Announces Addition of Peter Nielsen, Ph.D., Inventor of ..
GL
10/06NEUBASE THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Creatio..
AQ
09/29NEUBASE THERAPEUTICS : to Present at the Chardan Virtual 4th Annual Genetic Medi..
AQ
09/28NEUBASE THERAPEUTICS : to Present at the Chardan Virtual 4th Annual Genetic Medi..
AQ
09/28NeuBase Therapeutics to Present at the Chardan Virtual 4th Annual Genetic Med..
GL
09/18NEUBASE THERAPEUTICS : to Present at the Myotonic Dystrophy Foundation 2020 Virt..
AQ
09/17NEUBASE THERAPEUTICS : to Present at the Myotonic Dystrophy Foundation 2020 Virt..
AQ
09/17NeuBase Therapeutics to Present at the Myotonic Dystrophy Foundation 2020 Vir..
GL
More news
Financials (USD)
Sales 2020 - - -
Net income 2020 -17,3 M - -
Net Debt 2020 - - -
P/E ratio 2020 -9,84x
Yield 2020 -
Capitalization 203 M 203 M -
Capi. / Sales 2020 -
Capi. / Sales 2021 -
Nbr of Employees 15
Free-Float 78,0%
Chart NEUBASE THERAPEUTICS, INC.
Duration : Period :
NeuBase Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEUBASE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 15,67 $
Last Close Price 8,76 $
Spread / Highest target 105%
Spread / Average Target 78,8%
Spread / Lowest Target 48,4%
EPS Revisions
Managers
NameTitle
Dietrich A. Stephan President, Chief Executive Officer & Director
William R. Mann Chief Operating Officer
Samuel I. Backenroth Chief Financial Officer, Secretary & Treasurer
Robert Friedlander Consulting Chief Medical Officer
Danith Ly Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
NEUBASE THERAPEUTICS, INC.21.67%203
LONZA GROUP AG62.80%47 152
SEAGEN INC.72.54%34 263
IQVIA HOLDINGS INC.8.39%32 108
CELLTRION, INC.31.49%28 160
MODERNA, INC.260.58%27 830